engleski

Novel ruthenium amide conjugates as potential anticancer compounds

Cancer is the second leading cause of death globally accounting for one out of six disease related deaths.[1] Platinum drugs are most commonly applied in cancer treatment but exhibit numerous side effects. [2] In order to mitigate these side effect ruthenium organometallics have been developed as promising alternatives. Although no ruthenium compounds are currently in clinical usage, a number of compounds show superior properties over platinumbased drugs. [3] In our previous work [4] ruthenium(II) complexes of amino acid phosphine bioconjugates have shown relevant cytotoxic activity with selectivity towards tumour cells. Herein, we expand this work and present derivatives 1 and 2 (Fig 1) with one formally isomerised amide bond, inspired by our enantioselective catalysts. [5] The newly synthesised compounds were characterised by various spectroscopic methods and their biological properties were explored in HeLa cells

Ruthenium ; amide ; cancer ; hella cells

nije evidentirano